For patients with metastatic hormone-sensitive prostate cancer, metastatic burden affects outcome. We examined efficacy and safety from the ARASENS trial for subgroups by disease volume and risk.
Patients with metastatic hormone-sensitive prostate cancer were randomly assigned to darolutamide or placebo plus androgen-deprivation therapy and docetaxel.
High-volume disease was defined as visceral metastases and/or ≥ 4 bone metastases with ≥ 1 beyond the vertebral column/pelvis. High-risk disease was defined as ≥ 2 risk factors: Gleason score ≥ 8, ≥ 3 bone lesions, and presence of measurable visceral metastases.
Of 1,305 patients, 1,005 (77%) had high-volume disease and 912 (70%) had high-risk disease. Darolutamide increased overall survival (OS) versus placebo in patients with high-volume (hazard ratio [HR], 0.69; 95% CI, 0.57 to 0.82), high-risk (HR, 0.71; 95% CI, 0.58 to 0.86), and low-risk disease (HR, 0.62; 95% CI, 0.42 to 0.90), and in the smaller low-volume subgroup, the results were also suggestive of survival benefit (HR, 0.68; 95% CI, 0.41 to 1.13). Darolutamide improved clinically relevant secondary end points of time to castration-resistant prostate cancer and subsequent systemic antineoplastic therapy versus placebo in all disease volume and risk subgroups. Adverse events (AEs) were similar between treatment groups across subgroups. Grade 3 or 4 AEs occurred in 64.9% of darolutamide patients versus 64.2% of placebo patients in the high-volume subgroup and 70.1% versus 61.1% in the low-volume subgroup. Among the most common AEs, many were known toxicities related to docetaxel.
In patients with high-volume and high-risk/low-risk metastatic hormone-sensitive prostate cancer, treatment intensification with darolutamide, androgen-deprivation therapy, and docetaxel increased OS with a similar AE profile in the subgroups, consistent with the overall population.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Feb 16 [Epub ahead of print]
Maha Hussain, Bertrand Tombal, Fred Saad, Karim Fizazi, Cora N Sternberg, E David Crawford, Neal Shore, Evgeny Kopyltsov, Arash Rezazadeh Kalebasty, Martin Bögemann, Dingwei Ye, Felipe Cruz, Hiroyoshi Suzuki, Shivani Kapur, Shankar Srinivasan, Frank Verholen, Iris Kuss, Heikki Joensuu, Matthew R Smith
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL., Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium., Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, Quebec, Canada., Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France., Englander Institute for Precision Medicine, Weill Cornell Department of Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York, NY., UC San Diego School of Medicine, San Diego, CA., Carolina Urologic Research Center/Genesis Care, Myrtle Beach, SC., Clinical Oncological Dispensary of Omsk Region, Omsk, Russian Federation., University of California Irvine, Division of Hematology/Oncology, Orange, CA., Department of Urology, Münster University Medical Center, Münster, Germany., Fudan University Shanghai Cancer Center, Xuhui District, Shanghai, China., Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo, Brazil., Toho University Sakura Medical Center, Chiba, Japan., Bayer SEA, Singapore., Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ., Bayer Consumer Care AG, Basel, Switzerland., Bayer AG, Berlin, Germany., Orion Corporation, Espoo, Finland., Massachusetts General Hospital Cancer Center, Boston, MA.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/36795843
Related Content:
Analyzing the ARASENS Trial: Darolutamide Boosts Survival in Prostate Cancer Subgroups Journal Club - Zachary Klaassen